Latest Articles
Antibody-Drug Conjugate Shows Activity in Hard-to-Treat Uterine Cancer - Inside Precision Medicine
Antibody-Drug Conjugate Shows Activity in Hard-to-Treat Uterine Cancer Inside Precision Medicine
Published: May 15, 2026, 7:12 p.m.
Navigating the Evolving Landscape of Second-Line Endometrial Cancer Care - CancerNetwork
Navigating the Evolving Landscape of Second-Line Endometrial Cancer Care CancerNetwork
Published: May 15, 2026, 2:05 p.m.
Common Gynecologic Issues in Patients Post-Kidney Transplantation.
Advances in kidney transplantation have transformed survival and quality of life for women with end-stage renal disease, necessitating a focus on long-term health care for this population. Female kidney transplant …
Published: May 15, 2026, midnight
Bidirectional Mendelian Randomization and Single‑Cell RNA Sequencing Reveal an NK Cell-Mediated Causal Link Between Endometriosis and Endometrial Cancer.
Endometriosis is a chronic estrogen-dependent inflammatory disease that shares epidemiological and pathological features with endometrial cancer. However, the cellular and genetic mechanisms underlying this association remain unclear.
Published: May 15, 2026, midnight
Teddi Mellencamp bravely showcases brain surgery scars as she battles stage 4 cancer: 'Sick of the wigs' - MSN
Teddi Mellencamp bravely showcases brain surgery scars as she battles stage 4 cancer: 'Sick of the wigs' MSN
Published: May 14, 2026, 5:46 p.m.
Karyopharm Therapeutics Reports Q1 2026 Results, Advances Selinexor Phase 3 Trials in Myelofibrosis and Endometrial Cancer - Minichart
Karyopharm Therapeutics Reports Q1 2026 Results, Advances Selinexor Phase 3 Trials in Myelofibrosis and Endometrial Cancer Minichart
Published: May 14, 2026, 4:30 p.m.
Karyopharm completes endometrial cancer trial enrollment - Investing.com
Karyopharm completes endometrial cancer trial enrollment Investing.com
Published: May 14, 2026, 11:52 a.m.
Karyopharm completes endometrial cancer trial enrollment By Investing.com - Investing.com Canada
Karyopharm completes endometrial cancer trial enrollment By Investing.com Investing.com Canada
Published: May 14, 2026, 11:45 a.m.
Phase 3 endometrial cancer trial enrollment wraps as Q1 revenue hits $35.1M - Stock Titan
Phase 3 endometrial cancer trial enrollment wraps as Q1 revenue hits $35.1M Stock Titan
Published: May 14, 2026, 11:30 a.m.
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment - PR Newswire
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment PR Newswire
Published: May 14, 2026, 11:30 a.m.
Link copied to clipboard!